<SEC-DOCUMENT>0001648257-18-000005.txt : 20180213
<SEC-HEADER>0001648257-18-000005.hdr.sgml : 20180213
<ACCEPTANCE-DATETIME>20180213061035
ACCESSION NUMBER:		0001648257-18-000005
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180213
FILED AS OF DATE:		20180213
DATE AS OF CHANGE:		20180213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hutchison China MediTech Ltd
		CENTRAL INDEX KEY:			0001648257
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37710
		FILM NUMBER:		18598993

	BUSINESS ADDRESS:	
		STREET 1:		22ND FLOOR HUTCHISON HOUSE
		STREET 2:		10 HARCOURT ROAD
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			00000
		BUSINESS PHONE:		852-2121-3888

	MAIL ADDRESS:	
		STREET 1:		22ND FLOOR HUTCHISON HOUSE
		STREET 2:		10 HARCOURT ROAD
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>c257-20180213x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--HTML document created with Merrill Bridge  7.3.329.0-->
<!--Created on: 13-Feb-18 7:02:17 PM-->
<html>
	<head>
		<title>
			Form 6K
		</title>
	</head>
	<body><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;border-bottom:1pt solid #000000 ;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-weight:bold;font-size:18pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Washington, D.C. 20549</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-weight:bold;font-size:18pt;">FORM&nbsp;6-K</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;font-size:12pt;">REPORT OF FOREIGN PRIVATE ISSUER</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;font-size:12pt;">PURSUANT TO RULE 13A-16 OR 15D-16</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;font-size:12pt;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">For the Month of February 2018</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Commission File Number: 001-37710</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-weight:bold;font-size:18pt;">HUTCHISON CHINA MEDITECH LIMITED</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">(Translation of registrant&#x2019;s name into English)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">22/F, Hutchison House, 10 Harcourt Road, Hong Kong</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">(Address of principal executive offices)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Form&nbsp;20-F&nbsp;&nbsp;&#x2612; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&nbsp;&#x2610;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&#x2610;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Note:&nbsp;Regulation S-T Rule&nbsp;101(b)(1)&nbsp;only permits the submission in paper of a Form&nbsp;6-K if submitted solely to provide an attached annual report to security holders.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&#x2610;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Note:&nbsp;Regulation S-T Rule&nbsp;101(b)(7)&nbsp;only permits the submission in paper of a Form&nbsp;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#x2019;s &#x201C;home country&#x201D;), or under the rules&nbsp;of the home country exchange on which the registrant&#x2019;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#x2019;s security holders, and, if discussing a material event, has already been the subject of a Form&nbsp;6-K submission or other Commission filing on EDGAR.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;border-bottom:3pt solid #000000 ;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">HUTCHISON CHINA MEDITECH LIMITED</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Form&nbsp;6-K</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;text-decoration:underline;">EXHIBIT&nbsp;INDEX</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:115%;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Exhibit&nbsp;No.</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:11.20%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:11.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">Exhibit 99.1 </font></p>
				</td>
				<td valign="top" style="width:01.64%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">Press release relating to completion of enrollment of 527 patients in pivotal phase III FALUCA trial with fruquintinib in lung cancer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">2</font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">SIGNATURE</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">HUTCHISON CHINA MEDITECH LIMITED</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:41.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:41.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">By:</font></p>
				</td>
				<td valign="top" style="width:41.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">/s/ Johnny Cheng</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">Name:</font></p>
				</td>
				<td valign="top" style="width:41.86%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">Johnny Cheng</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">Title:</font></p>
				</td>
				<td valign="top" style="width:41.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Date: February 13, 2018</font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">3</font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>c257-20180213xex99.htm
<DESCRIPTION>EX-99
<TEXT>
<!--HTML document created with Merrill Bridge  7.3.329.0-->
<!--Created on: 13-Feb-18 7:02:31 PM-->
<html>
	<head>
		<title>
			hcm_Ex99_1
		</title>
	</head>
	<body><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;line-height:10pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"><img src="c25720180213xex99001.jpg" style="width: 1.885182in; height: 0.843645in" alt="Picture 2"></font>
		</p>
		<p style="margin:0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Press Release&nbsp;<br />&nbsp;<br />Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer</font>
		</p>
		<p style="margin:0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">London: Tuesday, February 13, 2018:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Hutchison China MediTech Limited (&#x201C;Chi-Med&#x201D;) (AIM/Nasdaq: HCM) has completed patient enrollment of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">FALUCA</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, its Phase III pivotal trial of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">f</font><font style="display:inline;font-family:Times New Roman,Times,serif;">ruquintinib in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">a</font><font style="display:inline;font-family:Times New Roman,Times,serif;">dvanced, third-line, non-small cell </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">lu</font><font style="display:inline;font-family:Times New Roman,Times,serif;">ng </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">ca</font><font style="display:inline;font-family:Times New Roman,Times,serif;">ncer (&#x201C;NSCLC&#x201D;) patients in China. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (&#x201C;VEGFR&#x201D;) 1, 2 and 3, that has met its primary endpoint in several Phase II and III clinical trials in China for the treatment of lung, colorectal and gastric cancers. Top-line FALUCA data is expected to be reported in late 2018 when the overall survival (&#x201C;OS&#x201D;) data is mature and, subject to a positive outcome, would be followed by a second New Drug Application (&#x201C;NDA&#x201D;) submission thereafter. Fruquintinib&#x2019;s first NDA, for the treatment of colorectal cancer, was submitted to the China Food and Drug Administration (&#x201C;CFDA&#x201D;) in June 2017.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">About Fruquintinib</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Fruquintinib (HMPL-013) is a highly selective small molecule drug candidate that has been shown to inhibit VEGFR 24 hours a day via an oral dose, with lower off-target toxicities compared to other targeted therapies. Its tolerability, along with its clean drug-drug interaction profile demonstrated to date, may enable rational combination with other cancer therapies such as in our ongoing clinical trials of fruquintinib in combination with chemotherapy and targeted therapy. VEGFR plays a pivotal role in tumor-related angiogenesis.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">About FALUCA</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">FALUCA is a randomized, double-blind, placebo-controlled, multi-center, Phase III registration study of fruquintinib targeted at treating patients with advanced non-squamous NSCLC, who have failed two lines of systemic chemotherapy.&nbsp;&nbsp;Patients were randomised at a 2:1 ratio to receive either 5mg of fruquintinib orally once per day, on a three-weeks-on / one-week-off cycle, plus best supportive care (&#x201C;BSC&#x201D;); or placebo plus BSC.&nbsp;&nbsp;Randomization was stratified by EGFR gene status and history of treatment by VEGF inhibitors. The primary endpoint is OS, with secondary endpoints including progression free survival (&#x201C;PFS&#x201D;), objective response rate (ORR), disease control rate (DCR) and duration of response (DoR). Additional details about this study can be found at clinicaltrials.gov, using identifier </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">NCT02691299</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">It was initiated following a similar Phase II clinical trial in 91 third-line NSCLC patients that succeeded in meeting its primary efficacy endpoint of PFS, with no unexpected safety issues. Results were highlighted in an oral presentation at the 17</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> World Conference on Lung Cancer on December 6, 2016 (clinicaltrials.gov identifier </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">NCT02590965</font><font style="display:inline;font-family:Times New Roman,Times,serif;">).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Other Fruquintinib Development Programs</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Lung cancer in China:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Along with FALUCA, fruquintinib is concurrently being studied in a Phase II study in combination with Iressa</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (gefitinib) in first-line setting for patients with advanced or metastatic NSCLC (clinicaltrials.gov identifier </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">NCT02976116</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). Preliminary results were highlighted in an </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">oral presentation</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> at the 18</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> World Conference on Lung Cancer on October 16, 2017.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Colorectal cancer in China:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The CFDA acknowledged </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">acceptance of the NDA</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#05398D;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">for fruquintinib for the treatment of patients with advanced colorectal cancer (&#x201C;CRC&#x201D;) in June 2017. Fruquintinib was subsequently awarded priority review status in view of its significant clinical value, according to a CFDA announcement in September 2017. The NDA is supported by data from the successful FRESCO study, a Phase III pivotal registration trial of fruquintinib in 416 patients with CRC in China, which was highlighted in an </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">oral presentation</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#05398D;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">at the American Society of Clinical Oncology Annual Meeting held on June 5, 2017 (clinicaltrials.gov identifier </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">NCT02314819</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). The FRESCO study followed an initial Phase I trial in 40 solid tumor patients, a Phase Ib study in 62 CRC patients, and a Phase II clinical trial in 71 CRC patients.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Gastric cancer in China:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> In October 2017, Chi-Med initiated a pivotal Phase III clinical trial of fruquintinib in combination with Taxol</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> (paclitaxel), known as the FRUTIGA study, for the treatment of over 500 patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after first-line standard chemotherapy (clinicaltrials.gov identifier </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">NCT03223376</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). The FRUTIGA study followed a Phase I/II clinical trial in 34 patients that demonstrated that combination therapy of fruquintinib and Taxol</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> in such patients was generally well-tolerated with promising tumor response (clinicaltrials.gov identifier </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">NCT02415023</font><font style="display:inline;font-family:Times New Roman,Times,serif;">).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In China, fruquintinib is jointly developed with Eli Lilly and Company. </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">United States bridging trial:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> In December 2017, Chi-Med initiated a multi-center, open-label, Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of fruquintinib in U.S. patients with advanced solid tumors. Additional details about this study may be found at clinicaltrials.gov, using identifier </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">NCT03251378</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">About Chi&#8209;Med</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Chi&#8209;Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Chi&#8209;Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:&nbsp;1). For more information, please visit: </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#063B8D;text-decoration:underline;">www.chi&#8209;med.com</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Forward&#8209;Looking Statements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">This press release contains forward-looking statements within the meaning of the &#x201C;safe harbor&#x201D; provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med&#x2019;s current expectations regarding future events, including its expectations for the clinical development of fruquintinib, plans to initiate clinical studies for fruquintinib, its expectations as to whether such studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates, timing and availability of subjects meeting a study&#x2019;s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of drug candidate fruquintinib to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions, to gain commercial acceptance after obtaining regulatory approval, the potential market of fruquintinib for a targeted indication and the sufficiency of funding. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med&#x2019;s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">CONTACTS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:490.50pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:179.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Investor Enquiries</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Mark Lee, Senior Vice President, Corporate Finance &amp; Development</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">+852&nbsp;2121&nbsp;8200</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">U.K. &amp; International Media Enquiries</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Anthony Carlisle, Citigate Dewe Rogerson</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">+44&nbsp;7973&nbsp;611&nbsp;888 (Mobile) </font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">anthony.carlisle@cdrconsultancy.co.uk</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">U.S. Based Media Enquiries</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Brad Miles, BMC Communications</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">+1&nbsp;(917)&nbsp;570&nbsp;7340 (Mobile) </font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">bmiles@bmccommunications.com </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Susan Duffy, BMC Communications</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">+1&nbsp;(917)&nbsp;499&nbsp;8887 (Mobile) </font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">sduffy@bmccommunications.com</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Investor Relations</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Matt Beck, The Trout Group</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">+1&nbsp;(917)&nbsp;415&nbsp;1750 (Mobile)</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">mbeck@troutgroup.com</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">David Dible, Citigate Dewe Rogerson</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">+44&nbsp;7967&nbsp;566&nbsp;919 (Mobile) </font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">david.dible@citigatedewerogerson.com</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Panmure Gordon (UK) Limited</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:179.40pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Richard Gray / Andrew Potts</font></p>
				</td>
				<td valign="top" style="width:132.60pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">+44&nbsp;(20)&nbsp;7886&nbsp;2500</font></p>
				</td>
				<td valign="top" style="width:178.25pt;padding:0pt 1.7pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:8pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:8pt;">&nbsp;</font>
		</p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c25720180213xex99001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c25720180213xex99001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M9VMX%CAD;<-A#+\[$9R<,4YP<;&YY-3:C=SV6M231[W7[-'$L?.WS':3:?\
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MDL@D>QMY=0^6W!23TQLX' _.B@#3HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
